A bioavailable testosterone test estimates the testosterone that is not tightly bound to sex hormone-binding globulin (SHBG). It includes free testosterone plus testosterone loosely attached to albumin, the fractions considered more available to tissues than SHBG-bound hormone. The test is most useful when symptoms and total testosterone do not agree or when SHBG is likely to be unusually high or low. Low bioavailable testosterone may support androgen deficiency in men when confirmed with properly timed testing and compatible symptoms. High results can occur with testosterone treatment, androgen use, PCOS, or an androgen-producing disorder. There is no universal normal range because laboratories use different measurement or calculation methods and report different units. Age, sex, pregnancy, liver and thyroid function, body composition, medicines, and hormone therapy all affect SHBG and therefore the result. Interpretation should always include total testosterone, SHBG, albumin, symptoms, and the collection time.
- Bioavailable testosterone includes free testosterone plus the fraction loosely bound to albumin.
- It is most helpful when total testosterone and symptoms disagree or SHBG is abnormal.
- In men, diagnosis of testosterone deficiency requires symptoms and repeat low morning results.
- In women, high bioavailable testosterone may support biochemical androgen excess, often from PCOS.
- Reference ranges are method-, age-, and sex-specific; calculated and directly measured results are not interchangeable.
- Testosterone treatment should not be adjusted from one bioavailable result without reviewing timing and safety monitoring.
Table of Contents
- What the bioavailable testosterone Test Measures
- Why the Test Is Ordered
- Preparation, Timing, and the Testing Process
- Normal Range and How Results Are Interpreted
- What High bioavailable testosterone Results Can Mean
- What Low bioavailable testosterone Results Can Mean
- How Results Fit With Other Hormones and Tests
- Next Steps After the Result
What the bioavailable testosterone Test Measures
Most circulating testosterone is attached to proteins. SHBG binds it strongly, albumin binds it weakly, and a small fraction circulates unbound. “Bioavailable” testosterone combines the unbound and albumin-bound fractions. This concept can be useful, but the exact biologic availability of each fraction is more complex than the name suggests.
Laboratories may measure bioavailable testosterone after ammonium sulfate precipitation or calculate it from total testosterone, SHBG, and albumin. Calculations depend on assumed binding constants and the accuracy of every input measurement. Results from different equations or laboratory methods may not match.
A hormone result is a measurement made under defined laboratory conditions, not a diagnosis by itself. The same concentration can carry different meaning at different ages, cycle stages, pregnancy stages, or times of day. Laboratories also use different analyzers, calibration systems, antibodies, and calculation methods. For that reason, the reference interval printed beside the result should take priority over a range copied from another report or website.
In men with typical SHBG and reliable total testosterone testing, total testosterone often answers the initial question. Bioavailable or free testosterone becomes more useful near the lower limit or when obesity, aging, thyroid disease, liver disease, HIV, anticonvulsants, estrogen exposure, or other factors alter SHBG.
The SHBG test explains why total and bioavailable testosterone can move in different directions.
Why the Test Is Ordered
Clinicians order bioavailable testosterone to clarify androgen status, not as a general wellness screen.
- Symptoms of testosterone deficiency with a borderline total testosterone result.
- A condition or medicine expected to raise or lower SHBG.
- Monitoring selected patients receiving testosterone therapy when total testosterone is difficult to interpret.
- Evaluating androgen excess in women when total testosterone is normal but clinical signs are convincing.
- Investigating delayed puberty or pituitary-gonadal disorders as part of a broader panel.
- Checking an unexpected free testosterone result with a different validated approach.
Symptoms in men may include reduced libido, fewer spontaneous erections, infertility, low bone density, anemia, or loss of muscle. Fatigue and low mood are nonspecific and should not establish deficiency alone. In women, acne, hirsutism, scalp hair thinning, and irregular ovulation may lead to androgen testing, but clinical context and exclusion of other causes remain essential.
Interpretation starts with the reason the test was ordered. A clinician looking for an adrenal enzyme disorder uses different cutoffs and follow-up tests than a clinician evaluating irregular periods, infertility, menopausal symptoms, or androgen deficiency. The result should be read with symptoms, examination findings, age, reproductive stage, and related laboratory values rather than compared with one universal “optimal” number.
Total testosterone is usually the starting measurement, as explained in the testosterone blood test overview.
Preparation, Timing, and the Testing Process
For men not using shift-work schedules, testing is usually performed in the early morning after a normal night’s sleep, often while fasting if the laboratory or guideline recommends it.
- Confirm whether the laboratory measures bioavailable testosterone directly or calculates it.
- Schedule morning collection for men and repeat a low result on a separate day before diagnosis.
- Record the time since the last testosterone injection, gel, patch, pellet, or oral dose.
- List thyroid medicines, estrogens, anticonvulsants, glucocorticoids, opioids, anabolic steroids, and supplements.
- Report acute illness, major sleep loss, calorie restriction, or heavy training that could temporarily suppress testosterone.
For shift workers, collection should be related to the main sleep period rather than a fixed clock time. Women may be tested in the morning and, when cycles are regular, early in the follicular phase to improve comparability. Treatment monitoring must use the timing specified for the formulation because peak and trough levels differ.
Before collection, provide a complete list of prescription medicines, over-the-counter products, supplements, contraceptives, fertility drugs, and hormone therapy. Do not stop prescribed treatment without instructions. Some products change hormone production, while others alter binding proteins or interfere with an immunoassay. High-dose biotin is a well-known source of interference in several hormone tests, although the direction and size of the error depend on the platform.
Acute illness can temporarily suppress or stimulate reproductive signaling. A test drawn during fever, major surgery, severe calorie restriction, or intense training may describe that temporary state rather than the person’s usual hormone function. When the clinical situation is stable and there is no urgent reason to test immediately, postponing or repeating the measurement can prevent an incorrect label.
Normal Range and How Results Are Interpreted
Bioavailable testosterone ranges vary widely by laboratory. Men have much higher concentrations than women, and both age and method influence the interval. The report’s own reference range is therefore essential.
| Factor | Typical effect | Why the result can mislead |
|---|---|---|
| High SHBG | Lowers the bioavailable fraction relative to total testosterone | Total testosterone may appear adequate despite low available hormone |
| Low SHBG | Raises the fraction relative to total testosterone | Total testosterone may appear low while available hormone is preserved |
| Albumin change | Can alter calculated bioavailable testosterone | Calculation assumptions may be less accurate |
| Testosterone therapy | Depends on formulation and draw timing | A peak or trough can look falsely high or low |
| Assay or equation | Changes the numeric result and interval | Do not compare unlike methods directly |
A “normal” result must match the patient population and method. Female values are near the lower limits of many assays, so mass-spectrometry total testosterone combined with a validated free or bioavailable calculation is often more dependable than a direct analog free-testosterone immunoassay.
A value close to a cutoff deserves more caution than a value that is clearly and repeatedly abnormal. Borderline results may move across the reference limit because of normal biologic variation, recent illness, sleep disruption, exercise, stress, or sample timing. Clinicians often repeat a test under better-controlled conditions before ordering imaging or beginning treatment. The repeat is most useful when the timing, medication list, and assay method are documented.
Trends can be useful when the same question is followed over time, but only when the measurements are reasonably comparable. A change between laboratories may reflect a method difference. A change after starting or stopping hormones may be expected. Record the laboratory, units, collection time, cycle day or pregnancy week, and relevant treatment so later results can be compared in context.
The free testosterone test measures or estimates a narrower fraction and may be reported instead of bioavailable testosterone.
What High bioavailable testosterone Results Can Mean
High bioavailable testosterone means more testosterone is available outside tight SHBG binding. The cause may be increased production, external androgen exposure, or unusually low SHBG.
- Prescribed testosterone dose that is too high or blood drawn near a treatment peak.
- Anabolic steroids, prohormones, or contaminated supplements.
- PCOS or another ovarian source of androgen excess.
- Adrenal androgen excess, including nonclassic CAH.
- Rare ovarian, testicular, or adrenal androgen-producing tumors.
- Low SHBG associated with obesity, insulin resistance, hypothyroidism, or androgen exposure.
In women, the speed and severity of symptoms determine urgency. Mild chronic hirsutism with irregular cycles often fits PCOS, while rapid virilization requires prompt evaluation. In men using testosterone, clinicians also review hematocrit, prostate-related monitoring when appropriate, fertility goals, blood pressure, and adverse effects.
External testosterone suppresses LH and FSH and can markedly reduce sperm production. A normal or high treatment level does not protect fertility. Men who want to conceive should discuss alternatives with a reproductive urologist or endocrinologist before starting or continuing therapy.
Confirm an unexpected high result with accurate total testosterone, SHBG, and albumin measurements. Do not lower or stop prescribed treatment abruptly without discussing the formulation, symptoms, and safety findings.
For women with androgen symptoms, a PCOS hormone panel may help separate common ovarian hyperandrogenism from adrenal or tumor causes.
What Low bioavailable testosterone Results Can Mean
Low bioavailable testosterone can reflect genuinely reduced production, increased SHBG binding, temporary suppression, or a calculation problem.
- Primary testicular failure, often with elevated LH and FSH.
- Pituitary or hypothalamic suppression, often with low or inappropriately normal LH and FSH.
- Obesity, severe illness, sleep deprivation, undernutrition, or excessive exercise.
- Opioids, glucocorticoids, some cancer treatments, or prior anabolic-steroid use.
- High SHBG from hyperthyroidism, liver conditions, estrogen exposure, or some medicines.
- Incorrect sample timing or laboratory method limitations.
A diagnosis of male hypogonadism requires persistent biochemical deficiency plus relevant symptoms or signs. Fertility concerns change treatment because testosterone replacement can worsen sperm production. In women, a low result has less established diagnostic value and should not be used alone to justify testosterone supplementation.
When SHBG is high, total testosterone can be normal while bioavailable testosterone is low. When SHBG is low, the reverse can occur. Measuring or accurately calculating the available fraction is therefore most useful at these extremes.
Repeat testing after recovery from acute illness or correction of poor timing. Evaluate LH, FSH, prolactin, thyroid function, iron status, and other causes according to the presentation before considering treatment.
How Results Fit With Other Hormones and Tests
Total testosterone, SHBG, albumin, LH, and FSH show whether the issue is production, binding, treatment timing, or pituitary signaling.
| Pattern | Possible explanation | Follow-up |
|---|---|---|
| Low total + low bioavailable + high LH/FSH | Primary gonadal failure | Confirm and assess cause |
| Low total + low bioavailable + low/normal LH/FSH | Pituitary, hypothalamic, illness, or medicine effect | Check prolactin and other pituitary factors |
| Normal total + low bioavailable + high SHBG | Increased binding | Investigate thyroid, liver, estrogen, and medicines |
| Low total + normal bioavailable + low SHBG | Reduced binding, often metabolic | Treat context; avoid diagnosing from total alone |
| High bioavailable on therapy | Dose or draw-timing issue | Review formulation, peak/trough, and safety monitoring |
Results should be consistent with symptoms. A surprising pattern may warrant repeat total testosterone by mass spectrometry and free testosterone by equilibrium dialysis or a validated calculation. Direct analog free-testosterone assays are often less reliable.
Next Steps After the Result
Follow-up should confirm the method, establish whether symptoms match the result, and identify the source before treatment.
- Check the collection time, treatment timing, units, method, total testosterone, SHBG, and albumin.
- Repeat low morning testing in men on a separate day when clinically stable.
- Use LH and FSH to distinguish primary gonadal failure from central suppression.
- Measure prolactin and other targeted tests when pituitary disease or medicine effects are possible.
- Review fertility goals before any testosterone treatment.
- Monitor symptoms and safety outcomes rather than chasing a single calculated target.
Treatment may involve addressing sleep apnea, weight-related metabolic disease, medication effects, pituitary disease, or testicular failure. Testosterone is appropriate only when indications and risks are clear. Women considering androgen therapy require careful indication, dosing, and monitoring because supraphysiologic exposure can cause irreversible voice change and other adverse effects.
Bring the actual report to the follow-up visit rather than only recalling that the level was “high” or “low.” The report shows units, the laboratory interval, specimen type, and sometimes the assay method. Ask whether the result needs confirmation, whether a related hormone should be measured at the same time, and what finding would change management.
A useful plan defines the next step and its timing. That may be no action, a repeat test, a dynamic stimulation or suppression test, ultrasound, semen analysis, genetic testing, or referral to endocrinology, reproductive endocrinology, urology, or maternal-fetal medicine. It should also identify symptoms that warrant earlier contact instead of waiting for the routine appointment.
Rapidly progressive symptoms deserve faster evaluation than a mild, stable laboratory abnormality. Examples include sudden virilization, severe headache with visual change, signs of adrenal crisis, heavy bleeding with dizziness, or concerning pregnancy symptoms. The laboratory number may guide the workup, but urgent decisions are driven by the whole clinical picture.
Treatment should address the confirmed cause and the person’s goals. Lowering or raising a laboratory value without establishing why it is abnormal can hide an important condition or create new problems. Hormone therapy can affect fertility, blood counts, liver function, clot risk, bone health, and pregnancy, so monitoring plans should be individualized.
Urgent review is appropriate for severe headache with visual change, rapid virilization, a testicular mass, or major adverse effects during testosterone therapy. Chest pain, severe shortness of breath, or neurologic symptoms require emergency care regardless of the hormone result.
When a repeat measurement is planned, try to reproduce the conditions that matter for this test. Use the same laboratory when practical, note the collection time, and record any change in medicines or reproductive stage. Consistency does not remove all biologic variation, but it makes a true trend easier to distinguish from noise.
Reference intervals describe a population selected by the laboratory; they do not define a treatment target for every person. A result inside the interval can still require attention when symptoms are strong or when another hormone shows a clear mismatch. Conversely, a small deviation may not represent disease when the timing or clinical setting explains it.
A laboratory result can answer only the question built into the test. It may show hormone concentration, but it cannot by itself prove ovulation quality, egg quality, sperm production, placental health, or the cause of a symptom. Those conclusions usually require a combination of history, examination, imaging, and other targeted tests.
When fertility is the concern, age, duration of trying to conceive, menstrual pattern, pregnancy history, semen findings, and tubal or uterine factors often affect the plan as much as a single hormone value. Testing both partners in parallel can prevent months of delay and reduce the chance that an incidental hormone result distracts from a more direct cause.
When symptoms are being monitored rather than fertility, define the outcome that treatment is meant to improve. Examples include restoration of periods, relief of hot flashes, reduction of unwanted hair growth, recovery of sexual function, preservation of bone health, or safe progression of puberty. Laboratory monitoring is most useful when tied to one of these clinical outcomes.
People using nonprescription “hormone balance” products should mention them before testing. DHEA, progesterone creams, testosterone boosters, compounded preparations, and biotin can alter physiology or make results harder to interpret. Product labels may not reliably predict the dose absorbed, so the safest approach is to review the exact container or ingredient list with the clinician.
Results can also differ because laboratories report conventional and SI units. A value expressed in ng/dL cannot be compared directly with one expressed in nmol/L without a hormone-specific conversion. Always compare the number, unit, and interval together. This simple check prevents many apparent contradictions between reports.
An abnormal result can have emotional weight, especially during fertility treatment, pregnancy, or puberty evaluation. Ask the clinician to separate what is known from what remains uncertain. A clear explanation of the likely causes, the confirmation plan, and the time frame for action is more useful than trying to interpret every decimal place independently.
Clinicians also consider whether the test result agrees with the physical findings. A marked biochemical abnormality without expected symptoms may prompt confirmation with a more specific laboratory method. Strong symptoms with a normal result may lead to testing at a different time, measuring a related hormone, or looking for a nonhormonal cause.
The pace of change can be as important as the level itself. Slow changes over years commonly fit physiologic aging or a chronic endocrine condition. Changes over weeks or a few months raise more concern for a new medicine effect, pregnancy-related change, acute illness, or a hormone-producing lesion, especially when symptoms progress quickly.
No single follow-up pathway fits every abnormal value. Mild and explainable results may only need observation. Persistent or substantial abnormalities may require specialist review and tests chosen to locate the source of hormone production or the level of signaling failure. The sequence should be deliberate so that each test answers a specific unresolved question.
Keep a copy of the laboratory report and the order indication. The clinician needs more than the highlighted flag: the numeric value, unit, reference interval, specimen type, collection date and time, and any comment about the assay can change interpretation. A result copied into a patient portal message without those details may be impossible to compare with a later test. This documentation is especially important when care moves between a primary clinician, endocrinologist, fertility clinic, and hospital laboratory.
Before repeating testing, decide what the repeat is meant to resolve. It may confirm persistence, correct a timing error, remove a medication effect, or use a more specific assay. Repeating the same poorly timed test without changing the conditions often reproduces uncertainty rather than solving it. The clinician should also state what result would lead to observation, another laboratory test, imaging, or treatment.
Small deviations from a reference interval are common because the interval usually contains about 95% of a selected comparison population. Some healthy people fall outside it, while some people with disease fall inside it. The clinical importance depends on how far the value is from the limit, whether it persists, whether related hormones agree, and whether symptoms fit the physiology. A reference flag is therefore a prompt for interpretation, not proof of disease.
Hormone results are also affected by changes in binding proteins and metabolism. Liver disease, thyroid disease, kidney disease, pregnancy, body composition, and oral estrogen exposure can change measured concentrations without producing the same change in tissue effect. When a binding issue is suspected, the clinician may use a free or calculated hormone, a related binding protein, or a more specific laboratory method rather than interpreting the total concentration alone.
Fertility decisions should not be reduced to a single endocrine value. A hormone may help choose medication dose, confirm ovulation, or identify a treatable disorder, but it does not measure every step required for pregnancy. Reproductive age, sperm exposure or semen quality, tubal patency, uterine anatomy, timing, prior pregnancies, and the duration of trying all influence the next step. A balanced evaluation prevents overreaction to an incidental result.
References
- Use of calculated free testosterone in men: advantages and limitations 2024 (Review)
- Reference intervals for free testosterone in adult men measured using a standardized equilibrium dialysis procedure 2023 (Study)
- A survey on measurement and reporting of total and free testosterone by clinical laboratories in the United Kingdom 2025 (Study)
- Recommendations for the measurement of sexual steroids in clinical practice. A position statement of SEQCML/SEEN/SEEP 2023 (Position Statement)
- Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing 2023 (Review)
Disclaimer
This article is educational and does not diagnose androgen deficiency or excess. Testosterone ranges depend on sex, age, timing, method, and treatment. Do not start, stop, or change testosterone or antiandrogen therapy without clinical supervision.
